Results 111 to 120 of about 204,699 (375)

B cells and systemic sclerosis interstitial lung disease

open access: yesArthritis &Rheumatology, Accepted Article.
Interstitial lung disease is an important complication of systemic sclerosis (SSc‐ILD) with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to FDA‐approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune ...
Nina Goldman   +2 more
wiley   +1 more source

Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis

open access: yesEuropean Respiratory Journal, 2020
Galectin (Gal)-3 is a profibrotic β-galactoside-binding lectin that plays a key role in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel and potent small-molecule inhibitor of Gal-3.
N. Hirani   +24 more
semanticscholar   +1 more source

Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Rheumatoid arthritis is a complex systemic disorder characterised primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease e.g. of the lung with potentially devastating clinical consequences.
Aurelie Najm   +2 more
wiley   +1 more source

Familial interstitial pulmonary fibrosis in two different families in India: A case series

open access: yesLung India, 2017
Introduction: Idiopathic pulmonary fibrosis (IPF), a chronic progressive interstitial lung disease (ILD), Occasionally, IPF occurs in families. Familial interstitial lung disease has been reported worldwide, limited information is available on the ...
Dabhi Pradipkumar   +5 more
doaj   +1 more source

Bronchiolitis obliterans. [PDF]

open access: yes, 1989
Bronchiolitis obliterans in the adult patient is a relatively uncommon and vexing clinical entity. This confusion results because this pathologic finding occurs in a variety of diverse clinical settings.
King, TE
core  

The role of endothelin-1 in pulmonary arterial hypertension. [PDF]

open access: yes, 2014
Pulmonary arterial hypertension (PAH) is a rare but debilitating disease, which if left untreated rapidly progresses to right ventricular failure and eventually death. In the quest to understand the pathogenesis of this disease differences in the profile,
Chester, AH, Yacoub, MH
core   +1 more source

Performance of an Idiopathic Pulmonary Fibrosis Derived Multibiomarker Panel for Rheumatoid Arthritis‐Associated Interstitial Lung Disease

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To assess whether a panel of peripheral blood biomarkers associated with idiopathic pulmonary fibrosis (IPF) is also associated with interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) utilizing three independent cohorts.
Brent A. Luedders   +18 more
wiley   +1 more source

Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis

open access: yesERJ Open Research
Background The Gender, Age and Physiology (GAP) model is a simple mortality prediction tool in patients with idiopathic pulmonary fibrosis that uses demographic and physiological variables available at initial evaluation.
Michael Kreuter   +9 more
doaj   +1 more source

Autophagy in Idiopathic Pulmonary Fibrosis

open access: yesPLoS ONE, 2012
Autophagy is a basic cellular homeostatic process important to cell fate decisions under conditions of stress. Dysregulation of autophagy impacts numerous human diseases including cancer and chronic obstructive lung disease. This study investigates the role of autophagy in idiopathic pulmonary fibrosis.Human lung tissues from patients with IPF were ...
Avignat Patel   +8 more
openaire   +5 more sources

Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK. [PDF]

open access: yes, 2018
INTRODUCTION: Recent developments in the care of patients with idiopathic pulmonary fibrosis have the potential to improve survival rates. Population-based estimates of the current disease burden are needed to evaluate the future impact of newly approved
Kausar, Imran   +2 more
core   +3 more sources

Home - About - Disclaimer - Privacy